drugset / Trial / NCT06341296
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the objective response rate, disease control rate, progression-free survival, overall survival, surgical conversion rate and safety of irinotecan liposome combined with 5-FU/LV+ bevacizumab regimen in first-line treatment of advanced metastatic colorectal cancer patients.
Timeline
- Start
- 2024-06-30
- Primary completion
- 2026-04
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 70 mg/m2 | — |
| Background | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |
| Background | LV [arm: experimental] — 400mg/m\^2, d1, 14 days per cycle, 8 cycles. | Unknown | 400 mg/m2 | — |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |